| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/17/2011 | US20110039777 Cancer treatment using natriuretic peptides |
| 02/17/2011 | US20110039775 Thyroid stimulating hormone fusion proteins |
| 02/17/2011 | US20110039771 Small humanin-like peptides |
| 02/17/2011 | US20110039770 Inhibitors of protein kinase c isoforms and uses thereof |
| 02/17/2011 | US20110039279 Methods and compositions for diagnosing breast cancer |
| 02/17/2011 | US20110038952 Gambogic acid glycoside derivatives and analogs, their preparation methods and applications |
| 02/17/2011 | US20110038951 Anti-tumor drug, medicament, composition, and use thereof |
| 02/17/2011 | US20110038941 Lipid Nanoparticle Compositions and Methods of Making and Using the Same |
| 02/17/2011 | US20110038939 Therapeutic stable nanoparticles |
| 02/17/2011 | US20110038936 System and method for electrospun drug loaded biodegradable chemotherapy applications |
| 02/17/2011 | US20110038926 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 02/17/2011 | US20110038925 Intravenous formulations of neurokinin-1 antagonists |
| 02/17/2011 | US20110038896 Biodegradable immunomodulatory formulations and methods for use thereof |
| 02/17/2011 | US20110038895 Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer |
| 02/17/2011 | US20110038894 Immunogenic Peptides of Tumor Associated Antigen L6 and Uses Thereof in Cancer Therapy |
| 02/17/2011 | US20110038888 Adjuvant compositions comprising poly-ic and a cationic polymer |
| 02/17/2011 | US20110038885 Chemokine analogs |
| 02/17/2011 | US20110038884 Immunopotentiating agent comprising ep1 agonist |
| 02/17/2011 | US20110038880 Parasporin-1 receptor and use thereof |
| 02/17/2011 | US20110038877 Interleukin-6 antagonists |
| 02/17/2011 | US20110038876 Heterocyclic compounds and use thereof as erk inhibitors |
| 02/17/2011 | US20110038873 Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (tlx) |
| 02/17/2011 | US20110038870 Compositions and methods to enhance the immune system |
| 02/17/2011 | US20110038869 Monoclonal antibodies against cd32b |
| 02/17/2011 | US20110038866 Improved fibronectin-based binding molecules and uses thereof |
| 02/17/2011 | US20110038865 Antibody- endostatin fusion protein and its variants |
| 02/17/2011 | US20110038864 Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof |
| 02/17/2011 | US20110038862 Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-postitive and her2-positive subtypes with clinical implications |
| 02/17/2011 | US20110038858 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents |
| 02/17/2011 | US20110038856 Methods of treating neoplastic, autoimmune and inflammatory diseases |
| 02/17/2011 | US20110038849 Inhibitory polynucleotide compositions and methods for treating cancer |
| 02/17/2011 | US20110038846 Pharmaceutical composition, use of the pharmaceutical composition for treating a brain tumor, production process thereof and a kit of parts comprising the pharmaceutical composition |
| 02/17/2011 | US20110038843 Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment |
| 02/17/2011 | US20110038842 High affinity ny-eso t cell receptor |
| 02/17/2011 | US20110038836 Device and Method for Transfecting Cells for Therapeutic Use |
| 02/17/2011 | US20110038833 Modified fluorinated nucleoside analogues |
| 02/17/2011 | US20110038801 Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer |
| 02/17/2011 | US20110038800 Method for the treatment or prophylaxis of lymphagioleiomymatosis (lam) and animal model for use in lam research |
| 02/17/2011 | US20110038795 Targeted radiotherapy |
| 02/17/2011 | US20110038793 Microsphere comprising an organic lanthanide metal complex |
| 02/17/2011 | US20110038792 Induction of thyroid iodide-handling gene expression in human cancers |
| 02/17/2011 | US20110038791 Methods for inhibiting six1 and eya proteins |
| 02/17/2011 | US20110038790 Treatment and prophylaxis of amyloidosis |
| 02/17/2011 | CA2808582A1 Imidamide sphingosine kinase inhibitors |
| 02/17/2011 | CA2771297A1 Methods of treating cancer using neurotrophin retargeted endopeptidases |
| 02/17/2011 | CA2771289A1 Methods of treating cancer using galanin retargeted endpeptidases |
| 02/17/2011 | CA2771164A1 Methods of treating cancer using tachykinin retargeted endopeptidases |
| 02/17/2011 | CA2771022A1 Photochemical internalization method |
| 02/17/2011 | CA2771021A1 Photosensitizing compositions |
| 02/17/2011 | CA2770873A1 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| 02/17/2011 | CA2770397A1 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
| 02/17/2011 | CA2770018A1 Novel peptide and use thereof |
| 02/17/2011 | CA2769674A1 Combination therapy of an afucosylated cd20 antibody with bendamustine |
| 02/17/2011 | CA2769595A1 Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
| 02/17/2011 | CA2769551A1 New macrolides and their use |
| 02/17/2011 | CA2768749A1 Inhibitors of jnk |
| 02/16/2011 | EP2284209A1 Polymer conjugate of folic acid or folic acid derivative |
| 02/16/2011 | EP2284194A1 Antibodies directed to angiopoietin-2 and uses thereof |
| 02/16/2011 | EP2284192A2 Camelidae antibodies for sublingual administration |
| 02/16/2011 | EP2284189A2 Nucleic acid molecules encoding fibroblast growth factor-like (FGF-like) polypeptides |
| 02/16/2011 | EP2284168A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 02/16/2011 | EP2284167A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 02/16/2011 | EP2284154A1 Antitumor 1,2-diphenylpyrrole compounds and their preparation process |
| 02/16/2011 | EP2284149A1 Selective androgen receptor modulators and methods of use thereof |
| 02/16/2011 | EP2283898A1 Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 02/16/2011 | EP2283897A2 HSA-free formulations of interferon-beta |
| 02/16/2011 | EP2283896A2 HSA-free formulations of interferon-beta |
| 02/16/2011 | EP2283872A2 Non-covalent bioconjugates useful for diagnosis and therapy |
| 02/16/2011 | EP2283869A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer |
| 02/16/2011 | EP2283868A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer |
| 02/16/2011 | EP2283867A2 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
| 02/16/2011 | EP2283866A2 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
| 02/16/2011 | EP2283865A1 Method of increasing testosterone and related steroid concentrations in women |
| 02/16/2011 | EP2283862A1 Antitumor agent |
| 02/16/2011 | EP2283860A2 Use for interleukin-33 (il-33) and the il-33 receptor complex |
| 02/16/2011 | EP2283846A1 miRNA compounds for treatment of prostate carcinoma |
| 02/16/2011 | EP2283845A1 Sustained release drug delivery system containing codrugs |
| 02/16/2011 | EP2283835A2 Method and preparation for treating metabolic stress |
| 02/16/2011 | EP2283831A2 Biomakers for pre-selection of patients for anti-IGF1R therapy |
| 02/16/2011 | EP2283815A1 Propellant-free non polar buccal spray of a sedative |
| 02/16/2011 | EP2283814A1 Polar buccal spray of a sedative |
| 02/16/2011 | EP2283813A1 Propellant-free polar buccal spray of a sedative |
| 02/16/2011 | EP2283040A2 Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage |
| 02/16/2011 | EP2283024A1 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
| 02/16/2011 | EP2283023A2 Bryostatin analogues and methods of making and using thereof |
| 02/16/2011 | EP2283020A1 Substituted imidazopyr-and imidazotri-azines |
| 02/16/2011 | EP2283014A1 Polymorphs of hydrochloride salt o5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyridoý2,3-b¨indole-7-carboxamideand methods of use therefor |
| 02/16/2011 | EP2282995A1 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| 02/16/2011 | EP2282981A1 {f-19} -labeled l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them |
| 02/16/2011 | EP2282782A1 Methods for radiolabelling macromolecules |
| 02/16/2011 | EP2282776A1 Apoptosis inducer |
| 02/16/2011 | EP2282775A2 Vector for use in medicine |
| 02/16/2011 | EP2282752A1 Saponin extract from saponaria spp and uses thereof |
| 02/16/2011 | EP2282740A1 Antifolate compositions |
| 02/16/2011 | EP2282739A2 Sequential administration of chemotherapeutic agents for treatment of cancer |
| 02/16/2011 | EP2111401B1 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
| 02/16/2011 | EP1962891B1 Dna vaccine for cancer therapy |
| 02/16/2011 | EP1835021B1 Novel strain conferring anti-disease properties to host and bacterial cell composition |
| 02/16/2011 | EP1723151B1 Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines |
| 02/16/2011 | EP1469077B1 Cell-specific expression/replication vector |